Transient spleen enlargement in peripheral blood progenitor cell donors given G-CSF
Open Access
- 21 July 2004
- journal article
- research article
- Published by Springer Nature in Journal of Translational Medicine
- Vol. 2 (1) , 25
Abstract
The administration of granulocyte colony-stimulating factor (G-CSF) to peripheral blood progenitor cell (PBPC) donors causes spleen length to increase, but the duration of enlargement is not known. Eighteen healthy subjects were given 10 μg/kg of G-CSF for 5 days and a PBSC concentrate was collected by apheresis. Ultrasound scans were used to assess craniocaudal spleen length before and after G-CSF administration. Mean spleen length increased from a baseline length of 10.7 ± 1.3 cm to 12.1 ± 1.2 cm on the apheresis day (p < 0.001). Ten days after apheresis, spleen length fell to 10.5 ± 1.2 cm and did not differ from baseline levels (p = 0.57), but in 3 subjects remained 0.5 cm greater than baseline length. Increases in spleen length in PBPC donors are transient and reversible.Keywords
This publication has 8 references indexed in Scilit:
- G‐CSF‐induced spleen size changes in peripheral blood progenitor cell donorsTransfusion, 2003
- Spleen size: how well do linear ultrasound measurements correlate with three-dimensional CT volume assessments?British Journal of Radiology, 2002
- Spleen enlargement in healthy donors during G–CSF mobilization of PBPCsTransfusion, 2001
- Spontaneous rupture of spleen during peripheral blood stem-cell mobilisation in a healthy donorThe Lancet, 1999
- Spontaneous splenic rupture following administration of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of peripheral blood stem cells.1997
- Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor [see comments]Blood, 1995
- Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) [see comments]Blood, 1995
- Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts [see comments]Blood, 1995